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The cause of atopic dermatitis has been vari-
ously attributed to allergic mechanisms, psychi-
atric disorders (1, 2, 13) and an unstable neuro-
vegetative system (2, 13). These, as well as other
theories (1, 1A) however, have not afforded
satisfactory explanations of this complex disease.
Systemic physiologic and biochemical (1, 4, 5,
6, 7, 11) abnormalities in patients with atopic
dermatitis have been observed which suggested
to the authors (3) that these patients may have
a low level of circulating catecholamiaes.
Juhlin (8,9, 10) as well as others (11, 12, 13, 14)
have observed abnormalities in the cutaneous
vascular physiology of patients with atopic der-
matitis which suggest that there may be an
alteration of catecholamines in the skin of these
patients during a flare of the disease.
These two sets of findings led the authors to
hypothesize in a previous paper (3) that under
stress, patients with atopic dermatitis bind nor-
epinephrine excessively at the major site of its
production (the skin) so that the normally small
quantity of norepinepbrine which should escape
into the circulation does not, and results in a
local bound accumulation as well as a circulating
deficit of this catecholamine. It was also demon-
strated (3), in a small number of patients, that
during a flare of the disease, patients with atopic
dermatitis have no measurable circulating nor-
epinephrine; and that in remission the plasma
levels become normal once more.
The preceding investigation suggested that it
would be of interest to determine whether there
is any difference in the metabolic fate of intra-
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venously and intracutaneously administered nor-
epinephrine in patients with atopic dermatitis
and patients with other dermatoses. Normal
values for the excretion of isotopically labelled
norepinephrine in normal patients have been
established in the past by Goodall, Kirshner and
Rosen (27). An attempt to study norepinephrine
metabolism in atopic dermatitis was made by
measuring the residue of intravenously and intra-
cutaneously injected isotopically labelled dl-
norepinephrine acetate in the serum, the amount
excreted in the urine as well as the uptake of this
material by the skin. A group of patients with
acute and chronic atopic dermatitis, as well as
patients with other dermatoses and normal skin
were studied. §
Subjects: None of the subjects had a past history
or presence of hypertension. Except for their cu-
taneous disorder, all were in good health.
In the first part of this study, four patients with
longstanding histories of familial atopy and atopic
dermatitis as diagnosed by the usual criteria (1)
were studied. The patients were: one Negro age
36 years, 2 Negresses age 15 and 37 years and 1
Caucasian woman age 40 years. The control
subjects consisted of 4 Negroes ages 30, 32, 60 and
62 with exfoliative dermatitis due to mycosis
fungoides; secondary syphilis with multiple skin
lesions (including an acute eezematous reaction
due to local overtreatment with heat by the pa-
tient) and systemic seleroderma. The last patient
was well, but had recovered from a recent upper
respiratory infection.
None of the patients tested intravenously were
studied by the intracutaneous method. For this
part of the study all the subjects were Negro.
There were five females, ages 15—34, with mild or
moderately severe atopie dermatitis, and one 25-
year old man with atopic dermatitis in remission.
Six subjects without atopic dermatitis consisted
of four men ages 18—40 with mycosis fungoides
(exfoliative stage), psoriasis, contact dermatitis
and normal skin; and 2 women ages 34 and 50 with
exfoliative dermatitis and seborrheic dermatitis
respectively.
§ Denis Abelson, M.D., and Katharine Lee,
Ph.D., of the Department of Endocrinology of the
Graduate Hospital of the University of Penn-
sylvania are thanked for their advice and tech-
nical assistance.
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METIIOD
Intravenous Administration of Isotopically
Labelled Norepinephrine: Ten microcuries of beta
C 14-dl-norepinephrine acetate (specific activity
20.5 millicuries/mM of norepinephrine—Radio-
purity 99.9%, obtained from Niehem, Inc.,
Bethesda, Maryland) in 500 ml of normal saline
were infused intravenously into eight suhj ects
over 20 minutes (0.004 microcuries/kgm/minute,
equal to 85 micrograms norepinephrine free base).
The patients voided prior to the onset of the
experiment and were kept at bed rest during the
entire experiment. Blood pressure readings were
recorded every two minutes for the first hour,
half-hourly thereafter for the next 6 hours and at
least 6 times during the following 18 hours.
Seven to 10 ml of blood for counting was drawn
from the arm opposite to which the infusion was
given. Samples were taken at 0, 5, 10, 20, 40, 60,
120, 360 and 720 minutes after the end of the in-
fusion. In two patients, samples were taken less
frequently but these patients were also tested at
24 hours after infusion. The blood was then re-
frigerated at 10—14°C. Disposable syringes and
needles were used throughout the experiment.
Urine was collected at 1, 6, 12 and 24 hours after
the infusion was over.
At 24 hours after infusion, an 8mm punch biopsy
specimen of diseased skin was taken from an area
of the body (usually the antecubital fossa or very
close to it, from the fiexural surface of the forearm)
opposite to that of the infusion. The tissue was
placed in a cotton-stoppered, glass tube, allowed
to dry under refrigeration, and was weighed when
dry 48 hours later.
Intracutaneous Administration of C-14 Nor-
epinephrine: The skin was anesthetized with 1%
lidocaine hydrochloride. A 1 cm round area of
diseased skin was marked off with ink (usually the
antecubital fossa) and 0.1 ml of diluted C-14 nor-
epinephrine was injected intradermally. One
tenth milliliter of this solution was previously
determined to contain .007 microcuries of C-14
norepinephrine (or 15,125 disintegrations/min).
Exactly 24 hours later, a 6 mm punch biopsy
specimen was taken from the center of the pre-
viously marked area; and the skin was prepared for
counting after being dried and weighed as de-
scribed above.
Demonstration of the Fate of Norepinephrine by
Detecting its Radioactive Carbon Atom
in Urine, Serum and Skin
Once the labelled compound had been adminis-
tered it was necessary to demonstrate its fate by
detecting its presence in the serum, its appearance
in the urine and its possible retention in the skin.
To do this liquid scintillation counting was used
(15—22, 26).
Preparation of Samples for Counting
Urine: 0.5 ml of urine was placed in a special
counting vial (15) * and 1 drop of 4N HC1 was
added. To this was added 15 ml of Bray's solution
(16). The vial was refrigerated.
Serum: Previous testing showed that there was
no more radioactivity in plasma or whole blood
than in serum. The blood was allowed to clot and
0.4 ml of clear serum was placed in a counting vial.
To this was added 1 ml of hydroxide of Hyamine
(21)f and 1 drop of 4N HC1. The mixture was
gently agitated until it was clear. When the serum-
Hyamine solution was visibly clear, 15 ml of
Bray's solution was added, the vial agitated for
thorough mixing (1 minute) and the sample
placed under refrigeration.
Skin: When the tissue was dry and had been
weighed, Hyamine, 1 ml/10 mg (21) of skin (dry
weight) was added and the test tube placed in a
water bath at 56° C. The specimen dissolved
slowly in the Hyamine. When complete dissolution
had taken place (8—12 hours) 1 ml of this mixture
was drawn off and placed in a vial to which 15 ml
of toluene PPO-POPOP mixturet was added. The
vial was then refrigerated.
Procedure for Counting: The vials containing
samples of blanks, urine, serum and skin were
placed in a refrigerated Tri-Carb liquid scintilla-
tion spectrometer (automatic dual channel model
314 EX-2-Packer Instrument Co.) (15) and per-
mitted to adapt to darkness and cold for 30 min-
utes. They were then automatically counted at
optimum voltage tap for 30—100 minutes each and
the count automatically recorded. To minimize
counting errors, urine was counted for 30 minutes,
serum and skin 100 minutes. Background radiation
was determined by counting a blank sample (in its
appropriate solvent) with each batch of samples.
Samples with like ratio (1 0.04) were con-
sidered to be a similarly quenched group (26) and
one sample from each group was internally stand-
ardized so that the specific radioactivity of each
sample could be calculated. All samples of skin
were also standardized.
RESULTS
Atopic Subjects: The four patients with atopic
dermatitis excreted 53.5% (mean value) of the
administered C-14 norepinephrine load in 24
hours. At 1 hour, 24.9% of the total excreted dose
was present in samples from the urine, from 1—6
hours, 39.2%; from 6—12 hours 20.2%; and from
12 hours to 24 hours 15.7% (mean value).
Cumulative data may be seen on Graph I.
*Obtained from Packard Instrument Co., La
Grange, Illinois.
tilydroxide of Hyamine 10-x, 1 molar solution in
Methanol (trademark of Rohm and Haas, Inc.) is
p- (diisobutyl cresoxethoxy ethyl)
-dimethyl
benzyl-ammonium chloride, a germicidal agent(16, 19, 20)—from Packard Instrument Co., La
Grange, Illinois.
* PPO is 2,5-Diphenyloxazolyle. POPOP is
(1 ,4-bis-2-Sphenyloxazolyl)-Benzene (18A). The
formula for the mixture is PPO, 5.0 g, POPOP 0.3
g, toluene q.s. ad 1 liter.
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Non—A topic Subjects: The four subjects with
scieroderma (acroscierotic type), mycosis fun-
goides, secondary syphilis and contact dermatitis
and the normal, excreted a mean of 70.1% of the
administered isotope load (see graph I) in 24
hours. At 1 hour, 21.4% of the total excreted
dose was present in samples of urine. In the
sample of urine from 1—6 hours after the infusion
42.2% was present, in the 6—12 hour sample
21.2%, and in the 12—24 hour sample 15.2%.
Disappearance of Radioactivity from the Serum
Atopic Subjects: (See Graph II). The radio-
activity is expressed as disintegrations per minute
(DPM) per milliliter of plasma. The mean radio-
activity was found to be 140 DPM/ml at 0
minutes. This rose to a maximum of 195 DPM/
ml in 10 minutes and quickly decreased to 85
DPM/ml at 20 minutes, 135 DPM/ml at 40 min-
utes and 25 DPM/ml at 12 hours. Individual
results may be seen in Table III.
Non-A topic Subjects: (See Table III and Graph
II). We do not have as many assayed samples for
this group as for the previous group but results
are expressed as the mean values for each time
sample. At 0 minutes after infusion 216 DPM/ml
were found. This reached one peak of 365 DPM/
ml at 10 minutes and a second peak of 440
DPM/ml at 40 minutes, then quickly disap-
peared, so that at 24 hours, no significant radio-
activity could be detected.
-
GRAPH II
Cutaneous C-14 Norepinephrine Uptake
Non-Atopic Subjects: No significant radio-
activity above background could be detected
from either the intravenously infused group, or
from the intracutaneously treated group except
for the patient with psoriasis who retained C-14
equal to two times background.
Atopic Subjects: Radioactivity is expressed in
DPM/10 mg. of skin (dry weight) above back-
ground (see Tables I and II). (1) Intravenously
treated group: Increased radioactivity was de-
tected, correlating roughly, with the degree of
cutaneous involvement. This ranged from 34
DPM/10 mg. in a patient with moderate chronic
fiexural pruritus to 1928 DPM/10 mg. in a pa-
tient with longstanding intractable pruritus,
generalized flexural lichenification, and eosin
ophilia of 15%. (2) Intracutaneously treated
group: part of the injected dose of isotope was
recovered in all but two patients. Again, there
was a good correlation between severity and
amount of isotope retention. A minimum of 2
DPM's/lO mg. was found in the patient with
atopic dermatitis in remission, and a maximum
of 878 DPM/10 mg. in a patient with moder-
ately severe atopic dermatitis, One patient with
psoriasis retained 52 DPM/10 mg.
,Statistics: The results were subjected to a
statistical analysis.* The total urinary recovery of
C-14 in 24 hours in each patient is expressed as the
* The authors would also like to thank George
Karreman, Ph.D., Associate Professor of Phys-
iology, Graduate School of Medicine for his
valuable assistance with the statistical portion of
the paper.
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TABLE I
Cutaneous uptake of intravenous norepinephrine
Correction for quenching effect of hyamine-dissolved skin in toluene-PPO-POPOP solution
Diagnosis Dry Skin ObseedCPMWeight (mg) Background
Increments in
CPM's Owing
to Addition
of Standard*
Per Cent
Counting
Efficiency
Specific Activity
Corrected for
Counting Efficiency
WeightX 10 = DPM/l0 mgs.
Mycosis fungoides
Syphilis II
Acroscierosis
Normal
Atopic dermatitis, severe.. ..
Atopic dermatitis, severe....
Atopic dermatitis, mild
Atopic dermatitis,
moderate
23
38
20
28
13
21
20
16
0
4
0
0
948
1105
36
98
9785
8492
9030
6480
10449
5753
11256
8721
46.6%
40.4%
43.0%
30.9%
50.1%
27.3%
53.5%
41.4%
0
3
0
0
1455.0
1928.0
34.0
148.0
* Standard = 21,000 DPM's of C-14 Toluene.
TABLE II
Cutaneous uptake of intracutaneously administered C-14 norepinephrine
Correction for quenching effect of hyamine-dissolved skin in toluene-PPO-POPOP solution
Diagnosis Weight (mg)
Dry Skin
Background
ObsedCPM
Increments in
of Standard* Efficiency
CPM Owing Per Cent
to Addition Counting
Specific Activity
Weight
Corrected for
Counting Efficiency
X 10 = DPM/10 mgs.
Atopic moderate
Atopic mild
Atopic moderate
Atopic mild
Atopic moderate
Atopic in remission
Mycosis fungoides
Exfoliative dermatitis
Psoriasis
Contact dermatitis
Normal
Seborrheic dermatitis
15
12
14
14
18
12
13
11
17
11
14
12
78
50
125
310
288
1
0
0
20
8
0
4
8032
7113
8076
9236
8333
8897
7650
9947
7369
9248
8056
8532
38.2%
34.0%
38.4%
43.9%
39.6%
42.3%
36.4%
47.4%
35.1%
44.0%
33.6%
40.5%
136
123
233
503
878
2
0
0
52
16
2
8
* Standard = 21,000 I)PM of C-14 Toluene (Packer Instrument Co.).
Percent Recovery of infused C-14. This value is the
mean of two separately calculated values: a) the
total volume x DPM/ml of a sample from the
pooled urine; b) the sums of the volumes x DPM/
ml. of samples from 1 hour, 6 hour, 12 hour and 24
hour urines.
The values obtained from the atopic and control
groups of patients showed that the atopic patients
excreted less C-14 in 24 hours than the non-atopic
group. Statistical significance can be inferred,
even in small populations, such as this, by an
analysis of the t distribution (28), as well as an
analysis of variance (29). The differences between
the two groups of patients studied was found to be
significant at the 1 percent level for both the t
distribution, as well as an analysis of variance.
Clinical Effects (See Graph III)
Repeated blood pressure readings during and
after the infusion showed that in the non-atopic
patients, the mean biood pressure readings
initially rose from a basal reading of 128/80
mmHg in twenty minutes to 145/85 mmHg. This
returned to pre-infusion levels in 1—2 hours. At
6 hours after infusion there was a second rise to
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Radioactivity in serum of ter intravenous
TABLE III
infusion of C-14 norepinephrine (expressed in DPM/cc)
Time after End of Infusion AtopicDermatitis AtopicDermatitis AtopicDermatitis AtopicDermatitis
Secondary
Syphilis
Mycosis
Fungoides
Acroscler-
osis Normal
0 Minutes 142 123 216
5 Minutes 146 115 361
10 Minutes 323 146 115
20 Minutes 69 161 115 85 90 353
40 Minutes 23 355 85 81 750 125
60 Minutes 42 139 85 85 354 180 850 208
2 Hours 55 152 65 65 550 196
6 Hours 13 65 38 46 455 599 0 188
12 Hours 4 55 27 27 202 30 0 39
24 Hours 0 24 0 0
—
ATOPICS — DIASTOLIC
153/88 mmllg which slowly returned to local
levels by 12 hours.
In the atopic group, all patients had low-nor-
mal or low initial readings of 107/74 mmHg
(mean value). After infusion, there appeared to
be a small rise to 110/79 mmllg which remained
at that level until 12 hours when it returned to
pre-testing levels.
DISCUSSION
Problems Involved in Preparation of Speci-
mens: The preparation of organic matter for de-
termination of radioactivity presents two large
problems. A solvent must be found which will
permit dissolution of the radioactive sample and
scintillator. At the same time it must give mini-
mal quenching. Since urine is aqueous, dried
skin largely protein in nature and serum an
aqueous-protein complex, it was obvious that
the same solvent could not be used for all the
samples. Therefore, we searched for a solvent of
aqueous systems (urine) as well as one for pro-
teins (skin) and combined elements of both to
measure radioactivity in serum.
Bray (16) has described a mixture containing
naphthalene, PPO, POPOP, methanol, ethylene
glycol and p-dioxane, which apparently has ex-
cellent aqueous solvent properties. We applied
this system to the study of C-14 norepinephrine
and its catabolites excreted in urine.
Hyamine, developed by Passmann, Radin
and Cooper (20), soluble itself in toluene, proved
itself to be an excellent sclvent of proteins (19)
and we used it as our solvent for skin. We corn-
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bined the use of Hyamine with Bray's solution
in studying serum. This resulted in counting
efficiencies of about 25% for serum, 35% for
urine and 40% for skin. Besides the problem of
quenching, there is of course a loss of countable
disintegrations per minute inherent in the count-
ing system itself. The efficiency of the spectrom-
eter used in this experiment was found to be
58% 2%. The total DPM of any given sam-
ple, therefore, was calculated from the counts
per minute obtained (mean of 100 minutes) tak-
ing into account quenching and operating effi-
ciency of the spectrometer and subtracting the
background radiation as measured by counting
blank samples of serum, urine and skin.
Interpretation of Results: The total 24-hour
urinary recovery of the administered C-14 nor-
epinephrine in the atopic group was found to be
16.6%, less than non-atopie group (See Graph I)
although the same dose was administered to both
groups under similar conditions. There was a
concomitant finding of increased radioactivity
in the skin of the atopie patients as compared
with controls. There was also a rough correla-
tion between the degree of dermatitis and the
amount of norepinephrine retention. It seems
reasonable to conclude that the diminished ex-
cretion was due to a sequestration of norepi-
nephrine in the skin of atopic dermatitis.
There was no significant retention of radio-
activity in the skin of patients with a variety of
dermatoses other than atopic dermatitis except
in a ease of psoriasis where the radioactivity
was found to be slightly increased. The rates of
disappearance of radioactivity from the serum
were less conducive to unequivical interpretation.
It is possible that the norepinephrine is bound
immediately after the intravenous infusion into
atopie skin, then very slowly released. This could
account for the two types of curves of radioac-
tivity we discovered in the serum of the two
groups of patients. In the atopie group, the
serum level of radioactivity at first was found
to be very low, then a small rise was detected
(195 DPM/ml). This was followed by a second
peak to 135 DPM/ml followed by a slow de-
crease. There was still detectable radioactivity
at 12 hours after the infusion. This last described
curve of radioactivity probably represents cata-
bolic products of norepinephrine metabolism
rather than norepinephrine itself (35).
In the non-atopie group detectable radioae-
tivity was highest within the first 60 minutes
after the intravenous injection. At 12 hours none
could he detected. This probably represents the
normal sequence of events: infusion —* presence
in serum —f uptake in tissues (low serum C-14) —>
catabolism (high serum C-14) — excretion (ap-
pearance in urine). The difference between the
two groups is probably one of delay of excretion
after prolonged retention in atopie dermatitis
skin. This supposition is further strengthened by
the clinical findings of an immediate rise in blood
pressure followed by a delayed rise in the non-
atopie group, compared to a minimal steadily
maintained 12 hour rise in the atopie group. The
fractionated percents
of admimstered C-IA ex-
% total reeoveiy
creted during the first hours, during the next 5
hours, the following 6 hours and the last 12 hours
was not found to be different from one group to
the next.
Theoretical Implication: Patients with acute
atopie dermatitis were found to sequester nor-
epinephrine in the skin at 24 hours after intra-
venous infusion, 2—50 times more than patients
with a variety of other eezematous and non-
eezematous dermatoses. The degree of cutaneous
C-14 retention also coincided with the clinical
severity of the dermatitis. The sequestration of
intravenously administered C-14 norepinephrine
coincided with a decreased level in the serum and
diminished excretion in the urine of these pa-
tients. Goodall, Kirshner and Rosen (27, 35)
have shown that the radioactive products of
infused C-14 norepinephrine in the normal hu-
man is excreted at the rate of 67 4% in 24
hours. They separated the various catabolic frac-
tions in the urine into 10 fractions. Our normal
subjects showed a total excretion of radioactivity
very similar to those described by Goodall and
his collaborators (35), but the atopie group ex-
creted a mean of 16.6% less. This was paralleled
by an increased retention of the eateeholamine in
the skin of these patients.
Intraeutaneous administration of C-14 nor-
epinephrine again showed a marked retention in
the skin of patients with acute atopie dermatitis
as compared to non-atopie dermatitie skin. These
findings would seem to strengthen our hypothesis
of a cutaneous binding affinity for eatecholamines
in acute atopie dermatitis.
The presence of norepinephrine in human and
animal skin has been demonstrated by Moller
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and Hakanson (25, 36). We can postulate on the
basis of past observations as well as these studies
on the type of bond which holds the norepineph-
rine. Biochemical and pharmacological evidence
has been accumulating that indicates the in vivo
presence of several forms of bound norepineph-
rine (23). Of the total bound norepinephrine (or
norepinephrine "store") a portion may be re-
leased by tyramine and other sympathomimetie
amines. In addition to this easily released nor-
epinephrine, there is a tightly bound store which
can be released by reserpine or guanethidine. A
third part of the store is available for release by
nerve stimulation and cannot be depleted by
tyramine. Besides these pharmacologically desig-
nated forms of bound norepinephrine, Burn has
postulated and shown that aeetylcholine may
also release norepinephrine (24). Topical applica-
tion of cortieo-steroid creams to the skin have
been shown to cause vasoconstrietion (30, 34).
It is possible, as well, that eortico-steroids may be
another source of norepinephrine release from a
bound state. It would seem reasonable to con-
clude from our findings here, the presence of
an excess store of tightly bound form of nor-
epinephrine in skin of patients with atopic
dermatitis. It should however be noted that
histochemical evidence for the presence of eate-
cholamines in human skin is equivocal (31, 32,
33).
It appears evident from the results of this
study that further work in this fertile field of
cutaneous eateeholamine metabolism may yield
valuable information both for the basic scientist
and the clinician.
SUMMARY
The metabolism of intravenously infused and
intraeutaneously injected C-14 norepinephrine
acetate was studied in 10 patients with atopie
dermatitis and in 10 patients with other eczema-
tous dermatoses, scleroderma, psoriasis, and nor-
mal skin.
The mean urinary excretion expressed as per-
cent of the administered load of norepinephrine
and its eatabolites was 16.6% less in 4 patients
with atopic dermatitis than in 4 control subjects
(53.5% vs. 70.1%). This difference was statisti-
cally significant at the 1% level.
The administered isotope tends to disappear
from the plasma in a different fashion in the
atopic group than in the control group. C-14
norepinephrine, 24 hours after intravenous ad-
ministration, was found to be 2 to 50 times higher
in the skin of the atopie group as compared to
the control group.
Intraeutaneously administered norepinephrine
was also found 24 hours later in the skin of pa-
tients with atopic dermatitis to be 3 to 5 times
higher than in a variety of other dermatoses and
normal skin.
The technical difficulties of assaying adminis-
tered isotopically labeled substances in skin,
serum and urine are discussed. The results of
this experiment indicate that in acute atopic
dermatitis norepinephrine (in excess of normal)
appears to be found tightly in the skin.
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